Trials / Completed
CompletedNCT02269995
Post-marketing Surveillance of DC Bead in Patients With Hepatocellular Carcinoma
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 300 (actual)
- Sponsor
- Eisai Co., Ltd. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This surveillance's objectives are: 1. Unknown adverse reactions 2. Incidences of adverse drug reaction 3. Factors considered to have effect to safety and effectiveness
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | E7040 | E7040 of optimal particle size (-300 um, 300-500 um, or 500-700 um to fit in a target vessel, target lesion, or embolized area) as transcatheter study device will be administered . |
Timeline
- Start date
- 2014-03-06
- Primary completion
- 2015-05-14
- Completion
- 2015-12-25
- First posted
- 2014-10-21
- Last updated
- 2018-11-05
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT02269995. Inclusion in this directory is not an endorsement.